Clinical trial · no report yet · Phase 3
CARMEN-LC03
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
- NCT04154956 ↗
- Terminated
- Sanofi
- 14 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 8 | |
| YouTube | 5 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- SAR408701; Docetaxel
- Arms
- SAR408701 (tusamitamab ravtansine) · Experimental
- Docetaxel · Active comparator
- Enrollment
- 389
- Primary outcomes
- Progression-free Survival (PFS)
- Overall Survival (OS)
- Sponsor
- Sanofi
- Start
- Feb 6, 2020
- Primary completion
- Sep 22, 2023
- Results posted
- Yes
- Registry record
- NCT04154956 · updated May 18, 2026